Group 1 - The Hong Kong pharmaceutical outsourcing sector has shown strong fluctuations, with companies such as Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rising over 3% [1] - Other companies like Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) have also experienced increases of more than 2.5% [1]

Group 1: Key Insights on the Machine Dog Industry - The quadruped robot industry is experiencing rapid application expansion, with strong environmental adaptability and commercial viability [4][12] - Key application scenarios include defense, industrial inspection, emergency rescue, and consumer household use, indicating a promising long-term market potential [4][12] - Domestic brands dominate the market, with over 50 companies actively participating, including notable players like Yushutech and Boston Dynamics [4][12] Group 2: Insights on the Power Generation Sector - In the thermal power sector, both coal and electricity prices are declining, leading to improved profit margins for coal-fired power plants [4][12] - Hydropower utilization hours are expected to increase due to favorable water conditions, with a projected utilization of 3367 hours in 2025, up 12 hours year-on-year [4][12] - Nuclear power is maintaining a high approval rate, with 10 new units expected to be approved in 2025, although profitability may be impacted by declining market electricity prices [4][12] Group 3: Recommendations for Investment - For thermal power, recommended companies include Guodian Power and Inner Mongolia Huadian, which benefit from stable profit margins [5][12] - In hydropower, companies like Yangtze Power and State Power Investment are highlighted for their potential growth due to improved financial conditions [5][12] - In the natural gas sector, companies such as Kunlun Energy and New Hope Energy are recommended due to expected profitability improvements from cost reductions [5][12]

Group 1 - The core point of the article is that JPMorgan has increased its stake in Kairong Pharmaceutical (06821) by purchasing 4,700 shares at a price of 80.6776 HKD per share, totaling approximately 379,200 HKD [1] - After the purchase, JPMorgan's total holdings in Kairong Pharmaceutical amount to approximately 1.6727 million shares, representing a holding percentage of 6% [1]

Core Viewpoint - JPMorgan has increased its stake in Kelaiying (002821) to approximately 6% by acquiring 4,700 shares at a price of HKD 80.6776 per share, totaling around HKD 379,200 [1] Group 1 - On February 4, JPMorgan purchased 4,700 shares of Kelaiying [1] - The total amount spent on the acquisition was approximately HKD 379,200 [1] - After the purchase, JPMorgan's total shareholding in Kelaiying reached approximately 1.6727 million shares [1]

同源康医药是一家专注于肿瘤创新药物研发的生物医药公司。由吴豫生于2017年11月发起创办，其现任 公司董事长、总裁，拥有超20年医药行业从业经验，曾任职于美国跨国药企先灵葆雅新药研发中心，具 备深厚的新药研发与项目管理能力。公司于2024年8月登陆港交所，开启研发与商业化协同发展新阶 段，始终致力于通过自主研发与全球合作，为患者提供突破性治疗方案。目前已有多个创新项目处于临 床或临床前开发阶段，形成了丰富的产品管线布局。 同源康医药近日迎来发展里程碑。公司宣布，其自主研发的针对非小细胞肺癌（NSCLC）脑转移的甲 磺酸艾多替尼片（TY-9591）新药上市申请（NDA）已获得国家药监局药审中心受理。 该药作为首个针对肺癌脑转移的新一代EGFR-TKI抑制剂，凭借差异化优势备受市场关注。公司管线布 局及差异化价值传递，也成为投资者聚焦的核心。 截至2月6日收盘，同源康医药股价为12.9港元/股，市值为49亿港元。 纳入优先审评阶段 产品上市进程提速 据介绍，甲磺酸艾多替尼片是已上市同类药物奥希替尼的氘代产品，通过技术改良，可减少药物有毒代 谢物AZ5104的产生，这一技术优化使得甲磺酸艾多替尼片能够以160mg的 ...

证券研究报告 行业周报 礼来替尔泊肽全线爆发，2025年合计贡献365亿美元 生物医药行业强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PINGA ...

Group 1 - Norges Bank increased its stake in Kairong (06821) by 53,500 shares at a price of HKD 79.0068 per share, totaling approximately HKD 4.2269 million [1] - After the increase, Norges Bank's total shareholding in Kairong reached 4.5065 million shares, representing a holding percentage of 16.19% [1]

Group 1 - Morgan Stanley reduced its stake in Kelaiying (002821) (06821) by 19,800 shares at a price of 78.6378 HKD per share, totaling approximately 1.557 million HKD [1] - After the reduction, Morgan Stanley's latest holding is approximately 1.668 million shares, representing a holding percentage of 5.99% [1]

Group 1 - Norges Bank increased its stake in Kelaiying (002821) (06821) by 53,500 shares at a price of HKD 79.0068 per share, totaling approximately HKD 4.2269 million [1] - After the increase, Norges Bank's total shareholding in Kelaiying reached 4.5065 million shares, representing a new ownership percentage of 16.19% [1]

Group 1 - Morgan Stanley reduced its stake in Kelaiying (06821) by 19,800 shares at a price of HKD 78.6378 per share, totaling approximately HKD 1.557 million [1] - After the reduction, Morgan Stanley's latest holding is approximately 1.668 million shares, representing a holding percentage of 5.99% [1]